As ex vivo response of human PBMCs to different HDAC-i cannot be compared to the in vivo response of EAMG mice or MG patients (n = 2) to the HDAC-I treatments, we chose to treat MG-PBMCs with Trichostatin (TSA), which is a pan-HDAC inhibitor for HDAC 1, 2, 3, and 6. This evidence concerns the gene HDAC9 and myasthenia gravis.